MERCANS
22.12.2023 15:10:28 CET | Business Wire | Press release
Avasant, a globally recognized analyst firm, has named Mercans as a payroll process transformation leader in its annual RadarView assessment of 2022-2023. Mercans clearly stood out among the 27 providers assessed for consistently delivering exceptional value to the market. Avasant's comprehensive industry analysis categorizes providers into challengers, disruptors, innovators, and leaders. Avasant placed Mercans in an elite group of industry leaders, confirming its technology leadership role in the global payroll industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231222991924/en/
Mercans Emerges as a Payroll Business Process Transformation Leader in Avasant's RadarView (Photo: AETOSWire)
In a span of one year, Mercans transitioned from a disruptor to an industry leader in Avasant’s assessment, demonstrating its impressive progress across all RadarView’s critical excellence dimensions - practice maturity, domain ecosystem, and investments and innovation.
Avasant's meticulous research methodology, incorporating publicly available information, SEC filings, annual reports, executive interviews, product demos, and direct inputs from service providers, adds depth and credibility to the acknowledgment of Mercans' industry leadership.
Avasant highlights Mercans' strategic approach and states: Leveraging its proprietary payroll engine and in-house local experts, Mercans delivers services across 160 countries. Mercans boasts a distinctive practice size, serving multinational corporations and Fortune 500 companies, supporting over 40 languages. The company's global delivery infrastructure spans 121 local offices, contributing to an impressive payroll revenue growth of over 30% from June 2022 to June 2023, reflecting its financial robustness.
At the heart of Mercans' success lies its proprietary global payroll platform - HR Blizz, the only gross-to-net payroll application that allows generating statutory compliant payrolls worldwide in a single software.
Mercans has disrupted the global payroll landscape with its G2N Nova global payroll engine. This state-of-the-art payroll engine stands out as the sole stateless application globally, swiftly generating payroll calculations across 160 countries within seconds, all while avoiding the storage of any sensitive employee data. This innovative approach has positioned G2N Nova as a catalyst for multinational corporations seeking to fully digitize their global payroll operations. Beyond its uniqueness as the sole global gross-to-net payroll application, G2N Nova offers a fully autonomous and touchless payroll experience, leading to dramatic reductions in processing times and costs.
Aditya Jain, Principal Analyst at Avasant, comments, "Mercans has developed its native global payroll engine to facilitate gross-to-net payroll calculations, digitalize processes, and offer self-service functionality to employees in 160 countries worldwide. Its partnerships with HCM and ancillary HR platform vendors enable it to offer comprehensive HR services through a unified portal. It leverages its local delivery network, including offices and regional experts in 121 countries, to help enterprises reduce dependence on local payroll aggregators for last-mile services across countries.
"Its continued investments in technology innovation, such as no-code HR integration tools and instant payments functionality, flexible business models, and a global delivery network, have made Mercans a leader in Avasant’s Payroll Business Process Transformation 2023–2024 RadarView."
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs and enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.
Visit www.mercans.com
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222991924/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom